tiprankstipranks
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake price target raised to $50 from $45 at H.C. Wainwright
The FlyMoonLake price target raised to $50 from $45 at H.C. Wainwright
7d ago
MLTX
MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results
PremiumThe Fly
MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results
14d ago
MLTX
MoonLake announces positive Phase 3 psoriatic arthritis results
PremiumCompany Announcements
MoonLake announces positive Phase 3 psoriatic arthritis results
14d ago
8K
MLTX
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
PremiumThe Fly
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
14d ago
MLTX
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
PremiumThe Fly
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
14d ago
MLTX
MLTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsMLTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
14d ago
MLTX
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
Premium
Ratings
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
1M ago
MLTX
MoonLake Immunotherapeutics Announces $200 Million Public Offering
Premium
Company Announcements
MoonLake Immunotherapeutics Announces $200 Million Public Offering
2M ago
8K
MLTX
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
PremiumThe Fly
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
2M ago
MLTX
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
2M ago
MLTX
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
PremiumThe Fly
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
2M ago
MU
CAR
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
PremiumThe Fly
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
2M ago
MLTX
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
PremiumRatingsMoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
2M ago
MLTX
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
Premium
The Fly
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
2M ago
MLTX
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
2M ago
MLTX
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
PremiumThe Fly
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
2M ago
MU
PR
MoonLake Highlights Strong Phase 3 Sonelokimab HS Results
PremiumCompany Announcements
MoonLake Highlights Strong Phase 3 Sonelokimab HS Results
2M ago
8K
MLTX
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
PremiumThe Fly
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
2M ago
MLTX
MoonLake shareholders back director, auditor and compensation plans
PremiumCompany Announcements
MoonLake shareholders back director, auditor and compensation plans
3M ago
8K
MLTX
MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
PremiumCompany AnnouncementsMoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
3M ago
MLTX
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
Premium
Company Announcements
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
3M ago
MLTX
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
Premium
Company Announcements
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
3M ago
8K
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >